Sai Kimie, Saito Yoshiro, Sakamoto Hiromi, Shirao Kuniaki, Kurose Koichi, Saeki Mayumi, Ozawa Shogo, Kaniwa Nahoko, Hirohashi Setsuo, Saijo Nagahiro, Sawada Jun-ichi, Yoshida Teruhiko
Division of Biosignaling, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Cancer Lett. 2008 Mar 18;261(2):165-71. doi: 10.1016/j.canlet.2007.11.009. Epub 2007 Dec 20.
Recent pharmacogenetic studies on irinotecan have revealed the impact of UDP glucuronosyltransferase (UGT) 1A128 on severe irinotecan toxicities. Although the clinical role of UGT1A16, which is specifically detected in East Asian patients, in irinotecan toxicities is suggested, clear evidence remains limited. To examine the impact of *6, the association of UGT1A1 genotypes with severe irinotecan toxicities was retrospectively investigated in Japanese cancer patients. A significant *6-dependent increase in the incidence of grade 3 or 4 neutropenia was observed in 49 patients on irinotecan monotherapy (p=0.012). This study further clarifies the clinical importance of *6 in irinotecan therapy in East Asians.
近期关于伊立替康的药物遗传学研究揭示了尿苷二磷酸葡萄糖醛酸转移酶（UGT）1A128对伊立替康严重毒性的影响。尽管有研究表明在东亚患者中特异性检测到的UGT1A16在伊立替康毒性方面具有临床作用，但明确的证据仍然有限。为了研究6的影响，我们对日本癌症患者进行了回顾性调查，以探讨UGT1A1基因型与伊立替康严重毒性之间的关联。在49例接受伊立替康单药治疗的患者中，观察到3级或4级中性粒细胞减少的发生率显著增加，且与6相关（p = 0.012）。这项研究进一步阐明了*6在东亚人伊立替康治疗中的临床重要性。
Zotero 插件